New
Minutia
The AI engine Fit Assessment
BetaMinutia develops cell-based therapies for type 1 diabetes and a real-time monitoring platform for cell therapies, aligning with pharma/biotech tech research, development, and monitoring in the pharmaceutical industry.
Blurb
Minutia is a biotech startup that develops cell-based therapies aimed at creating a functional cure for type 1 diabetes.
HQ Location
Oakland (United States)
Founded
2021
Employees
11 - 50
Total funding raised
Not available
Funding Status
Series A, September 26, 2024
We are working towards a transplant of insulin producing cells combined with nanosensors for diabetes that is so safe and effective we would put it in our own bodies and the bodies of people we love.
We believe our ability to create more robust and controlled insulin producing cell transplants that can be monitored in vivo over time will revolutionize the current clinical landscape for diabetes and cell replacement therapy.